Zhibo Ma, PhD of @salkinstitute explains mapping normal breast development to try and better understand cancer. __________ Breast cancer is one of the most common cancers, and some types are among the hardest to treat. The different types and presence of many different cells makes it difficult to target these tumors. Scientists at the Salk Institute have now used state-of – the-art technology to test each cell during normal breast development to understand what happens wrongly in cancer. The results of the group, published in the Cell Reports on 8 October 2019 and distributed in a free online resource, lay…
Author: Editor
Zhibo Ma, PhD of @salkinstitute explains how this affects treatment and clinicians today. __________ Breast cancer is one of the most common cancers, and some types are among the hardest to treat. The different types and presence of many different cells makes it difficult to target these tumors. Scientists at the Salk Institute have now used state-of – the-art technology to test each cell during normal breast development to understand what happens wrongly in cancer. The results of the group, published in the Cell Reports on 8 October 2019 and distributed in a free online resource, lay the foundations for…
Zhibo Ma, PhD of @salkinstitute answers common questions asked by colleagues regarding measuring chromatin accessibility changes in breast cancer. ________ Breast cancer is one of the most common cancers, and some types are among the hardest to treat. The different types and presence of many different cells makes it difficult to target these tumors. Scientists at the Salk Institute have now used state-of – the-art technology to test each cell during normal breast development to understand what happens wrongly in cancer. The results of the group, published in the Cell Reports on 8 October 2019 and distributed in a free…
Viruses designed to kill cancer cells are already used to treat one skin cancer and are commonly studied in other cancers. A new study shows that oncolytic viruses known as viruses can be enhanced further to improve the body’s immune response to tumors. The researchers found that this new type of oncolytic virus can simultaneously kill the cancer cells and provide tumor immune cells with a hormone that they need to perform their own cell killing functions. The dual-function virus was significantly more active in shrinking and removing tumors in mice with melanoma tumors than a regular oncolytic virus. The…
Breast cancer is one of the most common cancers, and some types are among the hardest to treat. The different types and presence of many different cells makes it difficult to target these tumors. Scientists at the Salk Institute have now used state-of – the-art technology to test each cell during normal breast development to understand what happens wrongly in cancer. The results of the group, published in the Cell Reports on 8 October 2019 and distributed in a free online resource, lay the foundations for understanding normal breast growth and can lead to new strategies for tumor control. “In…
Curtis McCloskey, PhD of @ottawahospital explains how this affects treatment and clinicians today. __________ A laboratory study published in Clinical Cancer Research provides a new perspective on how ovarian cancer is developed and suggests how it can be avoided. The research is the first to demonstrate that with age occurs the normal ovarian stiffening called fibrosis. It also indicates that this cycle may be prevented by the diabetes medication metformin. “Fibrosis happens when body tissues are repeatedly injured and inflamed, leaving behind hard collagen fibers that pile up over time, like a scar on the skin,” said Dr. Curtis McCloskey,…
Curtis McCloskey, PhD of @ottawahospital provides insight on a possible new frontier for preventing ovarian cancer. ____________ A laboratory study published in Clinical Cancer Research provides a new perspective on how ovarian cancer is developed and suggests how it can be avoided. The research is the first to demonstrate that with age occurs the normal ovarian stiffening called fibrosis. It also indicates that this cycle may be prevented by the diabetes medication metformin. “Fibrosis happens when body tissues are repeatedly injured and inflamed, leaving behind hard collagen fibers that pile up over time, like a scar on the skin,” said Dr.…
A laboratory study published in Clinical Cancer Research provides a new perspective on how ovarian cancer is developed and suggests how it can be avoided. The research is the first to demonstrate that with age occurs the normal ovarian stiffening called fibrosis. It also indicates that this cycle may be prevented by the diabetes medication metformin. “Fibrosis happens when body tissues are repeatedly injured and inflamed, leaving behind hard collagen fibers that pile up over time, like a scar on the skin,” said Dr. Curtis McCloskey, the lead author, “Cancer cells tend to like growing in these fibrotic tissues. Dr.…
Lee P. Richman, MD, Andrew J. Rech, MD and Robert H. Vonderheide, MD of @PennMedicine answer how it is different and is the software ready? _______ When tumor cells expand, tens of thousands of genetic mutations are often spawned. It’s like finding a few needles in a haystack to figure out which ones are most important to try with immunotherapy. Now a new model built by researchers at the University of Pennsylvania’s Abramson Cancer Center hand-picks certain needles so they can be leveraged in more effective, personalized cancer vaccines. Cell Systems today published data on the design of the template,…
Lee P. Richman, MD, Andrew J. Rech, MD and Robert H. Vonderheide, MD of @PennMedicine discuss an algorithm personalizes which cancer mutations are best for immunotherapy. ____________ When tumor cells expand, tens of thousands of genetic mutations are often spawned. It’s like finding a few needles in a haystack to figure out which ones are most important to try with immunotherapy. Now a new model built by researchers at the University of Pennsylvania’s Abramson Cancer Center hand-picks certain needles so they can be leveraged in more effective, personalized cancer vaccines. Cell Systems today published data on the design of the…
When tumor cells expand, tens of thousands of genetic mutations are often spawned. It’s like finding a few needles in a haystack to figure out which ones are most important to try with immunotherapy. Now a new model built by researchers at the University of Pennsylvania’s Abramson Cancer Center hand-picks certain needles so they can be leveraged in more effective, personalized cancer vaccines. Cell Systems today published data on the design of the template, and the algorithm is already available online as a resource-serving open source software. “There are mutations in tumors that can lead to powerful immune responses, but…
– Data from pivotal study demonstrate safety and efficacy regardless of prior gastrectomy in previously treated patients with metastatic gastric cancer (mGC) and gastroesophageal junction (GEJ) adenocarcinoma  PRINCETON, N.J., October 14, 2019 – Taiho Oncology, Inc. announced today that detailed results from the analysis of patients with prior gastrectomy enrolled in the Phase 3 TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine and tipiracil) in adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy, were published in the…
Ajai Chari, MD of @MountSinaiNYC answers how the phase 2 PLEIADES study affects treatment and clinicians today. ____________ About the PLEIADES Trial2Â The non-randomized, open-label, parallel assignment Phase 2 PLEIADES (MMY2040) study included 199 adults with either newly diagnosed or relapsed/refractory multiple myeloma. Patients with newly diagnosed multiple myeloma were treated with 1,800 mg of the SC formulation in combination with either bortezomib, lenalidomide and dexamethasone (D-VRd) or bortezomib, melphalan and prednisone (D-VMP). Patients with relapsed or refractory disease were treated with 1,800 mg of the SC formulation plus lenalidomide and dexamethasone (D-Rd). The primary endpoint for the D-VMP and D-Rd…
Ajai Chari, MD of @MountSinaiNYC explains a common question asked by colleagues regarding the PLEIADES study: how long do you keep people in clinic? _____________ About the PLEIADES Trial2Â The non-randomized, open-label, parallel assignment Phase 2 PLEIADES (MMY2040) study included 199 adults with either newly diagnosed or relapsed/refractory multiple myeloma. Patients with newly diagnosed multiple myeloma were treated with 1,800 mg of the SC formulation in combination with either bortezomib, lenalidomide and dexamethasone (D-VRd) or bortezomib, melphalan and prednisone (D-VMP). Patients with relapsed or refractory disease were treated with 1,800 mg of the SC formulation plus lenalidomide and dexamethasone (D-Rd). The…
Ajai Chari, MD of @MountSinaiNYC discusses the phase 2 PLEIADES study. _________ About the PLEIADES Trial2Â The non-randomized, open-label, parallel assignment Phase 2 PLEIADES (MMY2040) study included 199 adults with either newly diagnosed or relapsed/refractory multiple myeloma. Patients with newly diagnosed multiple myeloma were treated with 1,800 mg of the SC formulation in combination with either bortezomib, lenalidomide and dexamethasone (D-VRd) or bortezomib, melphalan and prednisone (D-VMP). Patients with relapsed or refractory disease were treated with 1,800 mg of the SC formulation plus lenalidomide and dexamethasone (D-Rd). The primary endpoint for the D-VMP and D-Rd cohorts was overall response rate. The…
Scott Kopetz, MD @skopetz of @MDAndersonNews discusses what’s next for the phase 3 BEACON trial in colorectal cancer. __________ Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI® (encorafenib), MEKTOVI® (binimetinib), and cetuximab (BRAFTOVI Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. The results show significant improvements in overall survival (OS) and objective response rates (ORR) for the BRAFTOVI Triplet and BRAFTOVI Doublet combination (BRAFTOVI and cetuximab), compared to cetuximab plus irinotecan-containing regimens (Control), and provide analysis of the…
Scott Kopetz, MD @skopetz of @MDAndersonNews explains the phase 3 BEACON CRC trial. ______ Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI® (encorafenib), MEKTOVI® (binimetinib), and cetuximab (BRAFTOVI Triplet), in patients with advanced BRAFV600E-mutant metastatic colorectal cancer (mCRC), following one or two lines of therapy. The results show significant improvements in overall survival (OS) and objective response rates (ORR) for the BRAFTOVI Triplet and BRAFTOVI Doublet combination (BRAFTOVI and cetuximab), compared to cetuximab plus irinotecan-containing regimens (Control), and provide analysis of the efficacy and safety of the…
Andrew Krivoshik, MD of @AstellasUS explains insights on EV-103 enfortumab vedotin plus pembrolizumab that was presented at ESMO. #ESMO2019
Andrew Krivoshik, MD of @AstellasUS discusses the EV_103 phase I trial in locally advanced and first- and second-line metastatic urothelial cancer. #ESMO2019
GRACE is very excited to bring to you this new program on supportive care in cancer treatment.Arjun Gupta, MD, one of the GRACE Fellows Ambassador Program Winners for 2019 is the host of this video series, Supportive Care in Cancer Treatment. In this next video, Dr. Gupta’s guest is Dr. Richard Dunne, with the University of Rochester Medical Center in NY. Their topic of discussion is cachexia in cancer treatment.For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________ 28% of patients in the global FLAURA trial were still receiving TAGRISSO at three years vs. 9% on either gefitinib or erlotinib TAGRISSO showed a 52% reduction in risk of central nervous system disease progression or death AstraZeneca today presented detailed overall survival (OS) results from the Phase III FLAURA trial of TAGRISSO® (osimertinib) in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Results showed a statistically significant…
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________ 28% of patients in the global FLAURA trial were still receiving TAGRISSO at three years vs. 9% on either gefitinib or erlotinib TAGRISSO showed a 52% reduction in risk of central nervous system disease progression or death AstraZeneca today presented detailed overall survival (OS) results from the Phase III FLAURA trial of TAGRISSO® (osimertinib) in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Results showed a statistically significant…
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________ 28% of patients in the global FLAURA trial were still receiving TAGRISSO at three years vs. 9% on either gefitinib or erlotinib TAGRISSO showed a 52% reduction in risk of central nervous system disease progression or death AstraZeneca today presented detailed overall survival (OS) results from the Phase III FLAURA trial of TAGRISSO® (osimertinib) in the 1st-line treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). Results showed a statistically significant…
Sarah Osman of @Queens_Belfast explains the standardized technique is using CT scans to assess and predict prostate cancers in patients. __________ Researchers from Queen’s University Belfast have discovered a new way to predict the aggressiveness and future behaviour of prostate cancers. The new method uses images from computed tomography (CT) scans that are routinely collected from all patients. The images are then analysed by a computer to extract hundreds of features, termed ‘radiomic features’, which have the potential to uncover disease characteristics that fail to be seen by the naked eye. This technique could complement traditional assessment methods and may…
Sarah Osman of @Queens_Belfast provides insight on research that found a new way to predict the future behavior of prostate cancers with computed tomography (CT) scans. _____________ Researchers from Queen’s University Belfast have discovered a new way to predict the aggressiveness and future behaviour of prostate cancers. The new method uses images from computed tomography (CT) scans that are routinely collected from all patients. The images are then analysed by a computer to extract hundreds of features, termed ‘radiomic features’, which have the potential to uncover disease characteristics that fail to be seen by the naked eye. This technique could…
Sarah Osman of @Queens_Belfast provides insight on research that found a new way to predict the future behavior of prostate cancers with computed tomography (CT) scans. ______________ Researchers from Queen’s University Belfast have discovered a new way to predict the aggressiveness and future behaviour of prostate cancers. The new method uses images from computed tomography (CT) scans that are routinely collected from all patients. The images are then analysed by a computer to extract hundreds of features, termed ‘radiomic features’, which have the potential to uncover disease characteristics that fail to be seen by the naked eye. This technique could…
Xiao-Ou Shu, MD of @VUMChealth explains how oncologists should treat male breast cancer patients and how it will affect clinicians. _______ Men may be more likely than women to die after being diagnosed with breast cancer, particularly during the first 5 years after diagnosis, a new study suggests. In the study, the 5-year overall survival rate after a diagnosis of breast cancer was 77.6% for men, compared with 86.4% for women, researchers reported in JAMA Oncology on September 19. The findings add to previous research showing differences in death rates between men and women with breast cancer while also providing information about some of the…
Valérie Gabarre @valeriegabarre of @OSEIMMUNO discusses the ATALANTE-1 trial and the TEDOPaM study presented by OSE Immunotherapeutics at #ESMO19. __________ ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients. Moving immune checkpoint inhibitors (ICI) in first-line setting in advanced NSCLC, new treatment strategies are needed for patients who progress on treatment with ICI. Tedopi® (OSE-2101) is a neoepitope vaccine restricted to HLA-A2 positive patients (∼45% of NSCLC) targeting five tumor-associated antigens expressed in lung cancer cells: ACE, HER2, MAGE2, MAGE3 and P53. In a phase II…
Research from the UAB’s O’Neal Comprehensive Cancer Center finds that patients treated outside the recommendations of the NCCN Guidelines had significantly greater direct costs. A new study by the O’Neal Comprehensive Cancer Center at the University of Alabama in Birmingham (UAB), published in the October 2019 issue of JNCCN— Journal of the National Comprehensive Cancer Network, finds that direct costs for patients with metastatic breast cancer (MBC) increase dramatically when their treatment differs from the NCCN Clinical Practice Guidelines for Oncology (NCCN) recommendations. Previous studies have found that disagreeable care leads to higher overall health care costs[1], but this is…
Xiao-Ou Shu, MD of @VUMChealth explains that in a recent study, men have a higher mortality rate than women due to multiple contributors. #breastcancer ___________ Men may be more likely than women to die after being diagnosed with breast cancer, particularly during the first 5 years after diagnosis, a new study suggests. In the study, the 5-year overall survival rate after a diagnosis of breast cancer was 77.6% for men, compared with 86.4% for women, researchers reported in JAMA Oncology on September 19. The findings add to previous research showing differences in death rates between men and women with breast cancer while also providing information…
Researchers from Queen’s University Belfast have discovered a new way to predict the aggressiveness and future behaviour of prostate cancers. The new method uses images from computed tomography (CT) scans that are routinely collected from all patients. The images are then analysed by a computer to extract hundreds of features, termed ‘radiomic features’, which have the potential to uncover disease characteristics that fail to be seen by the naked eye. This technique could complement traditional assessment methods and may help clinicians to make more informed personalised treatment decisions for men with prostate cancer. In the long run, it may reduce…
Once breast cancer spreads to bone, treatment becomes nearly impossible. Breast cancer cells can lie dormant in the bone, often undetectable and able to escape typical treatments. Unfortunately, these dormant cells can awaken at any time to generate tumors. All of this combined makes it difficult to understand how the cells proliferate and how to stop them from doing so. However, researchers from the University of Notre Dame have now identified a pair of proteins believed to be critical for spreading, or metastasizing, breast cancer to bone. One protein, known as CXCL5, was discovered to be key for signaling growth…
Patients with mesothelioma may gain similar benefit from immunotherapy as chemotherapy, and good responders may provide important clues to novel treatment for the thousands of new cases each year. Data from the PROMISE-meso trial presented at the ESMO Congress 2019 highlight the need to understand the biological mechanisms whereby mesothelioma, which is incurable, adapts to immunotherapy in some patients but not in others, resulting in variations in treatment response. PROMISE-meso compared the effects of immunotherapy with the checkpoint inhibitor, pembrolizumab, and standard chemotherapy after patients with mesothelioma relapsed on or after first-line treatment. “In PROMISE-meso, nearly four times more patients…
The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, according to preliminary results from a clinical trial. About 2% of patients with non-small cell lung cancer (NSCLC) have fusions between the RET gene and other DNA segments. These gene fusions can lead to the production of abnormal RET proteins that spur the growth of cancer cells. Selpercatinib (LOXO-292) is a targeted therapy that works by inhibiting the activity of abnormal RET proteins. The drug is an oral therapy that patients take as a pill. In the trial, more patients responded to the drug—that is, their tumors shrank—than has been seen with older drugs that…
Men may be more likely than women to die after being diagnosed with breast cancer, particularly during the first 5 years after diagnosis, a new study suggests. In the study, the 5-year overall survival rate after a diagnosis of breast cancer was 77.6% for men, compared with 86.4% for women, researchers reported in JAMA Oncology on September 19. The findings add to previous research showing differences in death rates between men and women with breast cancer while also providing information about some of the factors that may contribute to the disparity between the sexes. One factor identified by the authors was the lack of adequate…
Ellen J. Kim, MD of @PennMedicine includes observations found in the PROVe Study. #EORTC19 _________ Dr. Ellen J. Kim, UPENN, Professor of Dermatology, Penn Cutaneous Lymphoma Program, PROVe principal investigator, said: “The rarity of MF-CTCL has resulted in there being limited knowledge available for those affected by this disease, as well as many clinicians. We are pleased to have conducted the PROVe study and to further highlight our findings at the EORTC, as we set out to further expand our knowledge concerning the field of MF and current treatment options. The observational study assessed nearly 300 patients and verified that…
Ellen J. Kim, MD of @PennMedicine addresses questions asked by colleagues including: how long are patients on therapy in the PROVe Study? #EORTC19 _______ Dr. Ellen J. Kim, UPENN, Professor of Dermatology, Penn Cutaneous Lymphoma Program, PROVe principal investigator, said: “The rarity of MF-CTCL has resulted in there being limited knowledge available for those affected by this disease, as well as many clinicians. We are pleased to have conducted the PROVe study and to further highlight our findings at the EORTC, as we set out to further expand our knowledge concerning the field of MF and current treatment options. The…
Ellen J. Kim, MD of @PennMedicine explains the PROVe Study on efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies. #EORTC19 ________ Dr. Ellen J. Kim, UPENN, Professor of Dermatology, Penn Cutaneous Lymphoma Program, PROVe principal investigator, said: “The rarity of MF-CTCL has resulted in there being limited knowledge available for those affected by this disease, as well as many clinicians. We are pleased to have conducted the PROVe study and to further highlight our findings at the EORTC, as we set out to further expand our…
Chung-Han Lee, MD @ChungHanLee3 of @sloan_kettering answers how it affects clinicians and what is to come in kidney cancer. _______ Data shared today in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)  First glutaminase inhibitor to demonstrate clinical activity for treatment of cancer  SOUTH SAN FRANCISCO, Calif., Sept. 28, 2019 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer…
Chung-Han Lee, MD @ChungHanLee3 of @sloan_kettering explains questions asked by his colleagues: was the improvement in progression-free survival clinically meaningful? ________ Data shared today in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)  First glutaminase inhibitor to demonstrate clinical activity for treatment of cancer  SOUTH SAN FRANCISCO, Calif., Sept. 28, 2019 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of…
Chung-Han Lee, MD @ChungHanLee3 of @sloan_kettering discusses data from randomized #ENTRATA Study in patients with advanced RCC. __________ Data shared today in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)  First glutaminase inhibitor to demonstrate clinical activity for treatment of cancer  SOUTH SAN FRANCISCO, Calif., Sept. 28, 2019 (GLOBE NEWSWIRE) — Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other…
BOSTON–(BUSINESS WIRE)–Oct. 3, 2019– Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced a poster highlighting new preclinical duvelisib (COPIKTRAâ„¢) data that will be presented at the 5th International Conference on New Concepts in Lymphoid Malignancies, which is hosted by the European School of Haematology (ESH), and is taking place October 3-5, 2019, in Estoril, Portugal. The poster features preclinical research that compared duvelisib with idelalisib in preclinical models of mantle cell lymphoma (MCL). COPIKTRA is not approved for use in MCL, diffuse large B-cell lymphoma…
BOSTON–(BUSINESS WIRE)–Oct. 3, 2019– Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced duvelisib (COPIKTRATM) has received orphan drug designation from the U.S. Food and Drug Administration for use in the treatment of T-Cell lymphoma. The designation was created to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. “Receiving orphan drug designation for T-Cell Lymphoma, in addition to the previously-granted Fast Track status, for Peripheral T-Cell lymphoma, marks another important regulatory milestone to bring…
(WASHINGTON, October 3, 2019) — Yesterday, ASH President Roy Silverstein, MD, of the Medical College of Wisconsin asked members of the United States Senate Committee on Appropriations to adopt the provision in the House-passed fiscal year (FY) 2020 Labor, Health and Human Services, Education, and Related Agencies appropriations bill that dedicates $2 million for a federal program to collect data on the complications, treatments, and health outcomes of people with sickle cell disease (SCD). Through legislation passed in December 2018, the Centers for Disease Control and Prevention (CDC) Sickle Cell Data Collection Program was authorized to award grants to states, academic institutions,…
Shaji Kumar, MD of Mayo Clinic explains how patient volumes associated with longer survival in MM will affect clinicians and treatment. ______ New research in the September 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that providers with more experience treating people with multiple myeloma have better outcomes than those with more limited experience. In general, providers who saw the most cases were more likely to be located at academic, NCI-designated cancer centers. However, the researchers found that the very highest-volume providers at community facilities did achieve equally low mortality rates as clinicians at NCI-designated cancer centers. “Multiple myeloma…
Shaji Kumar, MD of Mayo Clinic explains a new study that supports higher patient volumes are associated with longer survival in multiple myeloma. _______ New research in the September 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that providers with more experience treating people with multiple myeloma have better outcomes than those with more limited experience. In general, providers who saw the most cases were more likely to be located at academic, NCI-designated cancer centers. However, the researchers found that the very highest-volume providers at community facilities did achieve equally low mortality rates as clinicians at NCI-designated cancer centers.…
Hypertension with ibrutinib more common than previously reported; this study is first to show association between cancer drug-related hypertension and other heart problems (WASHINGTON, October 3, 2019) — Over half of people prescribed the targeted blood cancer-fighting drug ibrutinib developed new or worsened high blood pressure within six months of starting the medication, according to a new study published online today in Blood. The analysis is also the first to tie ibrutinib-related hypertension to a heightened risk of heart problems, particularly atrial fibrillation. Moreover, the association of ibrutinib with cardiovascular complications remained regardless of the prescribed dose. “This study provides a more clear picture…
An international panel of experts will identify the best approaches to implement genetic testing for men with prostate cancer  PHILADELPHIA — The Sidney Kimmel Cancer Center – Jefferson Health (SKCC) will host the second International Prostate Cancer Consensus Conference, “Implementation of Genetic Testing for Inherited Prostate Cancer,†Oct. 4-5. This invitation-only scientific meeting will once again bring together more than 100 clinicians, researchers, national organizations, thought leaders, and patient advocates to review the rapidly evolving field of genetic testing in the management of prostate cancer.  This is a follow-up meeting to the inaugural Philadelphia Prostate Cancer Consensus that…
Ramaswamy Govindan, MD of Siteman Cancer Center explains the phase I KRAS inhibitor that is well tolerated by patients with adenocarcinoma and NSCLC. ________ A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according to Ramaswamy Govindan, M.D., from the Siteman Cancer Center at Washington University School of Medicine, St. Louis. The KRAS G12C mutation is found in approximately 14 percent of patients with lung adenocarcinoma and 11 percent of patients with non-small cell lung cancer but…
Ramaswamy Govindan, MD of Siteman Cancer Center answers multiple questions regarding the phase I KRAS inhibitor well tolerated by patients with adenocarcinoma and NSCLC including: will patients respond with other operations? __________ A clinical trial testing the toxicity of a KRAS inhibitor demonstrated early promising antitumor activity and few adverse side effects in patients with advanced non-small cell lung cancer harboring KRAS G12C mutation, according to Ramaswamy Govindan, M.D., from the Siteman Cancer Center at Washington University School of Medicine, St. Louis. The KRAS G12C mutation is found in approximately 14 percent of patients with lung adenocarcinoma and 11 percent…